EBI’s lead product suppresses the exaggerated immune response and therefore has the potential to prevent a range of severe inflammatory disorders. The most important indication is acute kidney injury (AKI).

Acute Kidney Injury

The market for Acute Kidney Injury (AKI) therapeutics is large and steadily growing due to the rising incidence and recognition of the disease. Moreover, there is a need to prevent AKI in specific patient groups that are at high risk of developing AKI. One of these groups consists of patients undergoing (cardiac) surgery. As a result of increased diagnostics and awareness, the severity of the burden of AKI has become undeniable. In the past twenty years the number of AKI-associated hospitalizations and deaths has increased five-fold, up to around 700,000 deaths occur annually in Europe, the US and Japan. Clearly, AKI has a striking socioeconomic and public health outcome and is in desperate need of an effective treatment option.

Currently, a combined phase IIa and phase IIb trial with patients undergoing elective CABG‐surgery is ongoing. During surgery, the circulation of the patients is maintained using cardiopulmonary bypass. Immune cells in the circulation are exposed to artificial materials, resulting in an inflammatory response, SIRS symptoms and increased risk of organ dysfunction, e.g. AKI. In this trial the effect of EBI’s lead compound on renal function in patients at increased risk of developing renal failure is assessed. Independent interim analysis of the study was positive and completion of the study is expected in early 2018.

Irradiation damage

The second product application of EBI’s products is irradiation damage. Of the people diagnosed with cancer circa 50% require irradiation therapy, 60% of who are treated with curative intent. However, irradiation therapy is also related to severe risks. The activation of the pro-inflammatory cytokine network in response to radiotherapy is associated with several complications including debilitating damage to mucosal tissue. Currently, there are no safe and effective pharmacological agents to reduce irradiation toxicity that can be used in all patient groups.

Future indications

After successful development of EBI’s lead product for AKI and irradiation damage, EBI’s pipeline provides a path forward for the development of new and promising critical care therapies for multiple organ damage related to systemic inflammatory responses.